This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MorphoSys ORBIT Program

MorphoSys AG

Description: MorphoSys and MD Anderson's Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit will work together to identify, validate and develop novel anti-cancer monoclonal antibodies. MorphoSys will apply its proprietary Ylanthia technology to generate and optimize fully human antibody candidates against jointly selected targets.

Deal Structure: MorphoSys and MD Anderson
In May 2016, MorphoSys and The University of Texas MD Anderson Cancer Center announced a long-term strategic alliance for the discovery and development of novel therapeutic antibodies against cancer.

MorphoSys will work with MD Anderson's Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit, a platform of MD Anderson's Moon Shots Program with a combination of industry and academic science expertise in the development of monoclonal antibodies.

Collaborating on numerous targets in a variety of oncology indications, the partners will work together to identify, validate and develop novel anti-cancer antibodies through to clinical proof of concept. MorphoSys will apply its proprietary Ylanthia technology to generate and optimize fully human antibody candidates against jointly selected targets. The parties will collaborate in target validation and preclinical drug development to quickly bring selected candidates into...See full deal structure in Biomedtracker

Partners: University of Texas MD Anderson Cancer Center


MorphoSys ORBIT Program News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug